FDA sends 30 warning letters to telehealth firms over compounded GLP-1 marketing

Federal regulators said on March 3, 2026 that they had issued 30 warning letters to telehealth companies and online wellness clinics, faulting the way those businesses described compounded GLP-1 medicines on their websites ^[4].

The complaints center on advertising, not on the ingredients themselves. FDA said the main violations were claims "implying sameness with FDA-approved products" and marketing that put a telehealth company's own name or trademark on a drug without qualification, which can leave a patient thinking that company made the medicine ^[4]. The agency also said some sellers obscured where their compounded drug came from ^[4]. The law firm Venable describes the same two issues: online statements presenting compounded GLP-1s as effectively identical to approved versions, and private-label packaging that clouds who is doing the compounding ^[5]. Venable notes FDA did not take up the separate question of whether these compounded products are "essentially a copy" of approved drugs, which would affect whether they can be made at all ^[5].

The letters were dated Feb. 20, 2026 and released publicly on March 3, according to the firm Frier Levitt, which says they were signed by Matthew J. Lash, acting director of the Office of Compounding Quality and Compliance in FDA's Center for Drug Evaluation and Research ^[1]. The firm says FDA cited Federal Food, Drug, and Cosmetic Act provisions barring false or misleading drug labeling and advertising, and flagged statements suggesting a compounded product contained "the same ingredients" as a brand-name drug or had been "tested in clinical trials" ^[1]. FDA's own announcement does not list those examples and gives no response deadline ^[4], while Patient Care Online reports recipients got 15 business days to correct violations ^[2]. Frier Levitt says the letters require a reply within 15 working days to CDER's Office of Compliance, spelling out corrective steps such as identifying compounding sources, supplying label samples and pulling disputed website claims, and warns of possible seizure or injunction for companies that stay silent ^[1].

FDA Commissioner Marty Makary said in the agency's announcement: "It's a new era. We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms—and taking swift action" ^[4]. He added that compounded drugs can matter for shortages or individual needs, but that "compounders should not try to compound drugs in a way that circumvents FDA's approval process" ^[4].

This is the second batch of warning letters aimed at telehealth firms since FDA began a broader push against misleading direct-to-consumer drug ads in September 2025; the agency says it has sent thousands of letters in six months, more than in the prior decade combined ^[4]. Frier Levitt puts the September 2025 action at roughly 100 cease-and-desist letters ^[1]. On the same day, FDA separately told Novo Nordisk that an Ozempic consumer ad misrepresented the drug's approved uses — its second such letter to the company in under a month, after a Feb. 5 letter about a Wegovy TV spot ^[3].

Why it matters for patients

A compounded drug has not been through FDA review for safety, effectiveness or quality, and it is not a generic, which is FDA-approved ^[4]. FDA says compounded drugs should be used only when a patient's medical need cannot be met by an approved product ^[6].

The letters point to the kind of sales pitch FDA treats as a warning sign. The agency's consumer page on unapproved GLP-1 drugs lists a claim that a compounded medicine "is the same as an FDA-approved drug" among its telehealth red flags, along with steep discounts, no screening or prescription from a licensed doctor, and labels carrying misspellings or questionable pharmacy addresses ^[6]. That page also describes dosing errors that have hospitalized some patients, multi-dose vials that should be discarded 28 days after first use, and injectable drugs arriving warm or with too little ice ^[6].

Because the action targets marketing language, it does not change which prescriptions a patient can fill. It does address claims people see when comparing prices online.

What happens next

It has not been reported whether any of the 30 recipients have answered or whether FDA has taken further steps ^[1]. On March 9, 2026, Novo Nordisk and Hims & Hers said they settled their dispute and formed a partnership: Hims & Hers will sell branded Ozempic and Wegovy and stop most promotion of compounded GLP-1s, and Novo dropped its patent suit while reserving the right to refile ^[1]. Separately, HHS Secretary Robert F. Kennedy Jr. has said FDA is weighing whether to reclassify roughly 14 restricted peptides so they could be compounded again — a proposal that has not been finalized ^[5].